I. Management of Next-Day Drowsiness

The half-life of daridorexant is about 8 hours, and some patients may still have residual drowsiness upon waking the next morning.

Ensure time in bed: Ensure at least 7 hours in bed after dosing; insufficient time in bed significantly increases the risk of next-day grogginess and slowed reactions.

Fix the dosing time: Taking the medication at the same time every night helps reduce fluctuations in residual effects.

Strengthen observation in the early stage: During the initial treatment period and dose adjustment period, pay attention to your alertness after waking in the morning; if drowsiness persists, avoid scheduling important activities.

Avoid additive factors: Do not drink alcohol, and do not use with other sedative-hypnotics or antihistamines, to avoid worsening next-day drowsiness.

II. Driving and Machinery Operation Risks

Caution in the early treatment period: After starting the medication or adjusting the dose, observe for at least several days and confirm there is no next-day drowsiness before driving.

Stop when drowsy: If you feel drowsy or have difficulty concentrating while driving, pull over and rest immediately; do not force yourself to continue driving.

Avoid high-risk operations: After dosing and when drowsy the next morning, avoid operating machinery, working at heights, and activities requiring high alertness.

Individual differences: Some patients are sensitive to the drug and may still have residual effects even with adequate time in bed; rely on your own perception.

III. Drug Interactions

Strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin, itraconazole): significantly increase the blood concentration of daridorexant; concomitant use is prohibited or a substantial dose reduction is required, per the doctor's instructions.

Moderate CYP3A4 inhibitors (such as diltiazem, verapamil, fluconazole): may increase drug exposure; dose reduction and strengthened observation are usually recommended.

Strong CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin): accelerate drug metabolism and reduce efficacy; concomitant use is generally not recommended.

Central nervous system depressants (benzodiazepines, opioids, alcohol): additive sedative effects worsen the risk of drowsiness and respiratory depression and should be avoided.

Other hypnotics: Concomitant use with other sleep-promoting drugs is not recommended; if a medication switch is needed, transition should follow the doctor's instructions.

IV. Key Points Summary

Less than 7 hours in bed is the main trigger of next-day drowsiness; be sure to ensure adequate sleep duration.

During the initial treatment period and dose adjustment period, extra caution is required for driving and high-risk operations.

Inform the doctor of all concomitant medications before dosing, with particular attention to CYP3A4 inhibitors and inducers.

Note: This guide is for reference only; please follow your doctor's instructions for specific medication use.